LOUVAIN-LA-NEUVE, Belgium & TOKYO - Thursday, April 9th 2015 [ME NewsWire]
Collaboration signed to enhance access to proton therapy and carbon therapy worldwide
Toshiba Medical Systems Corporation to become IBA’s Proteus®ONE distributor in Japan
IBA to become Toshiba’s carbon therapy agent outside of Japan
(BUSINESS
WIRE)-- IBA (Ion Beam Applications S.A.) and Toshiba Corporation
(TOKYO:6502) today announce the signing of a global collaboration to
expand access to advanced particle therapy worldwide. Toshiba Medical
Systems Corporation will become the distributor in Japan for
Proteus®ONE, IBA’s compact single-room proton therapy solution, and IBA
will become the agent for Toshiba’s Carbon Therapy Solutions outside
Japan.
IBA and Toshiba will collaborate on activities such as
customer education for Proteus®ONE and Toshiba's carbon therapy
solutions.
The collaboration will also enable both organizations to mutually leverage their Operation and Maintenance (O&M) services.
Olivier
Legrain, Chief Executive Officer of IBA commented: “This is an
important step for IBA. A closer collaboration with a company of
Toshiba’s caliber and leadership will accelerate the expansion of proton
therapy in Japan and the introduction of Toshiba’s carbon therapy
across the world. Carbon ion therapy is particularly suitable for
treating radio-resistant tumors and allows for dose escalation, which is
recommended in a number of clinical applications. Through this new
collaboration, IBA will further strengthen its world leading position in
proton therapy and will reaffirm its leading position in the delivery
of the latest innovative cancer therapies worldwide.”
Satoshi
Tsunakawa, Chief Executive Officer of Healthcare Company, Toshiba
Corporation, said: “Proton and carbon therapies are among the most
exciting technological advancements in the treatment of cancer. Toshiba
looks forward to collaborating with IBA to enhance access to
best-in-class technologies for both proton and carbon therapy centers.
Guided by the principles of The Basic Commitment of the Toshiba Group,
“Committed to People, Committed to the Future,” this collaboration will
give both our companies an enhanced set of tools to provide the best
cancer treatment technologies.”
About Proton and Carbon Therapy
Proton Therapy is considered an advanced and targeted cancer
radiotherapy treatment due to its superior dose distribution and fewer
side effects. Protons deposit the majority of their effective energy
within a precisely controlled range, directly within the tumor, sparing
healthy surrounding tissue. Higher doses can be delivered to the tumor
without increasing the risk of side effects and long-term complications,
thereby improving patient outcomes and quality of life.
Carbon
ions not only have similar physical characteristics as protons, they
have also a higher radiobiological effect compared to photon and proton,
which could lead to shorter treatment courses and improved patient
outcomes.
About IBA IBA (Ion Beam Applications S.A.) is a global
medical technology company focused on bringing integrated and innovative
solutions for the diagnosis and treatment of cancer. The Company is the
worldwide technology leader in the field of proton therapy, the most
advanced form of radiation therapy available today. IBA’s proton therapy
solutions are flexible and adaptable, allowing customers to choose from
universal full scale proton therapy centers as well as compact, single
room systems. In addition, IBA also has a radiation dosimetry business
and develops particle accelerators for the medical world and industry.
Headquartered
in Belgium and employing about 1100 people worldwide, IBA has installed
systems across the world, from Europe and the US and to the emerging
markets. IBA is listed on the pan-European stock exchange EURONEXT.
(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be
found at: www.iba-worldwide.com
About Toshiba Toshiba
Corporation, a Fortune 500 company, channels world-class capabilities in
advanced electronic and electrical products and systems into five
strategic business domains: Energy & Infrastructure, Community
Solutions, Healthcare Systems & Services, Electronic Devices &
Components, and Lifestyles Products & Services. Guided by the
principles of The Basic Commitment of the Toshiba Group, “Committed to
People, Committed to the Future,” Toshiba promotes global operations
towards securing “Growth Through Creativity and Innovation” and is
contributing to the achievement of a world in which people everywhere
live in a safe, secure and comfortable society.
Founded in Tokyo
in 1875, today’s Toshiba is at the heart of a global network of over 590
consolidated companies employing over 200,000 people worldwide, with
annual sales surpassing 6.5 trillion yen (US$63 billion). To find out
more about Toshiba, visit www.toshiba.co.jp/index.htm
Toshiba
newly formed its Healthcare Company last August to focus its healthcare
business as one of three pillars of its overall business. By combining
diagnosis imaging technology provided by Toshiba Medical Systems and
accelerator and super conducting technology derived from nuclear
business, Toshiba is delivering Heavy Ion Therapy system for cancer
treatment. Toshiba has been contributing to Japanese National Institute
of Radiological Sciences and Kanagawa Cancer Center.
Contacts
For further information please contact:
IBA
Jean-Marc Bothy, +32 10 47 58 90
Chief Financial Officer
or
Thomas Ralet, +32 10 47 58 90
Vice-President Corporate Communication
communication@iba-group.com
or
For media and investor enquiries:
Consilium Strategic Communications
Amber Bielecka, Matthew Neal, Jessica Hodgson and Ivar Milligan
+44 (0)20 3709 5700
IBA@consilium-comms.com
or
Rx Communications Group (US)
Melody Carey, +1-917-322-2571
mcarey@RxIR.com
or
Toshiba Press Contact:
Yukihito Uchida
Masumi Fukuoka
Tatsuro Oishi
PR & IR Office, Toshiba Corporation
+81-3-3457-2100
media.relations@toshiba.co.jp
Permalink: http://www.me-newswire.net/news/14245/en
No comments:
Post a Comment